Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1991017149) 3-NAPHTHYL-3-CARBOXYALKYLTHIO OR OXY SUBSTITUTED ALKANOIC ACID LEUKOTRIENE ANTAGONISTS
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

We Claim:
1. A compound of formula (I):


where each substituent may be substituted on any carbon of the naphthyl ring, or a pharmaceutically acceptable salt thereof;
Rl is Cg to C13 alkyl, C- to C12 alkoxy, C7 to C12 alkylthio, Ci to C12 1-alkynyl, 10-undecynyloxy, 11-dodecynyl, phenyl-C4 to Ci alkyl, phenyl-C3 to C9 alkoxy, phenylthio-C3 to C9 alkyl with each phenyl optionally mono substituted with bromo, chloro,
trifluoromethyl, Ci to C4 alkoxy, methylthio or trifluoromethylthio, furyl-C4 to Cio alkyl, trifluoromethyl-C7 to C12 alkyl or cyclohexyl-C4 to Cio alkyl;
P is O or S(0)q where q is 0, 1 or 2, with the proviso that Ri is not alkylthio or phenylthioalkyl when q is 1 or 2;
Y is R2,' CH(R3)(CH2 mR2» CH(R3)-tetrazol-5-yl, or tetrazol-5-yl; m is 0, 1, and 2;
R2 is -COR4 where R4 is -OH, -OE where E is pharmaceutically acceptable cation or a pharmaceutically acceptable ester-forming group, R2 is -N(R5)2 where R5 is H, Ci to Cβ alkyl, phenylCi-Cό-alkyl, the two R5 groups are combined to form a cyclic group having 3 to 5 carbons, -CN, -SO3H, -S02NH2, NHSO2R6, -CH(NH2)COR4, NHCH2COR4;
R3 is hydrogen, methyl, Ci to C4 alkoxy, fluoro or hydroxy;
R is -(CH2)nA, -(CH2)nArA or ArA where n is 0-6, Ar is phenyl or substituted phenyl, thienyl, pyridyl, imidazolyl, tetrazol-5-yl or thiazolyl and A is -(CH2)nR2. -^2. -tetrazol-5-yl, -CH(NH2)R2, -CN,

-SO3H, -SO2NH2, NHSO2R6, -CH(NH2)COR4, NHCH2COR4; and
R6 is Ci to Cio-alkyl, phenyl, or phenylCi to C3-alkyl.
2. A compound of claim 1 where P is S and Y is -(CH2)o- 3 COOH, a compound of formula (II).


3. A compound of claim 2 wherein R is -(CH2)i-3R2- 4. A compound of claim 3 where R is -CH2CH2COR4 and Y is -CH2COR4.
5. A compound of claim 4 wherein Ri is Cs to Ci 3 -alkyl or phenyl-C4 to Ci o-alkyl radical.
6. A compound of claim 5 which is 3-(2-carboxyethylthio)-3

[(7-{5-phenylpentyl)naphth-l-yl]propionic acid or a pharmaceuticall acceptable salt thereof.
7. A compound of claim 5 which is 3-(2-carboxyethylthio)-3 (7-dodecylnaphth-l-yl)propionic acid or a pharmaceutically
acceptable salt thereof.
8. A compound of claim 1 when R is -CH2CH2COR2 and Y is CH(OH)COR2, or a pharmaceutically acceptable salt thereof.
9-. A compound of claim 8 wherein Ri is C$ to Ci3-alkyl or phenyl-C4 t0 θ ^kyl.
10. A compound of claim 9 which is 3-(2-carboxyethylthio)-3

[-7-(5-phenylpentyl)naphth-l-yI]-2-hydroxypropionic acid or a pharmaceutically acceptable salt thereof.
11. A compound of claim 9 which is 3-(2-carboxyethylthio)-3 [-(7-[5-phenylpentyl)naphth-l-yl]-2-hydroxypropionic acid or a pharmaceutically acceptable salt thereof.
12. A compound of claim 1 where P is O, Y is -COR4,
CH(OH)COR4 or CH(R3)(CH2)mCOR4 and R is -(CH2)nA, or -(CH2)nArA where n is 0-2.
13. A compound of claim 12 which is:
3-(2-carboxyethyloxy)-3-[7-(5-phenylpentyl)naphth- l -yl]propionic acid;
3-(2-carboxyethyloxy)-3-(7-dodecylnaphth-l -yl)-propionic acid;
3-(2-carboxyethyloxy)-3-(7-dodecylnaρhth-l -yl)-2-hydroxypropionic acid;
3-(2-carboxyethyloxy)-3-[7-(5-ρhenylpentyl)naρhth- l -yl]-2-hydroxypropionic acid;
4-oxy-5-(7-dodecylnaphth-l -yl)-6-(tetrazol-5-yl)hexanoic acid; or
4-oxy-5-[ l -(7-(5-phenylpentyl)naphth- l -yl)]-6-(tetrazol-5 -yl)hexanoic acid.
14. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

15. A pharmaceutical composition according to claim 14 in a form suitable for administration by inhalation, parenteral
administration, oral administration or topical administration.
16. A pharmaceutical composition according to claim 15 in which the active ingredient is 3-(2-carboxyethylthio)-3-[-7-(5-phenylpentyl)naphth-l-yl]propionic acid or a pharmaceutically acceptable salt thereof.
17. A pharmaceutical composition for inhibiting antigen-induced respiratory anaphylaxis comprising a pharmaceutical carrier or diluent' and an amount of a compound of claim 1 and an Hi blocker sufficient to inhibit said anaphylaxis.
18. A method of treating a pulmonary disease in which leukotrienes are a factor in a subject in need thereof comprising administering to such subject an effective amount of a compound of claim 1 either alone or in combination with a pharmaceutically acceptable excipient.
19. The method of claim 18 in which die pulmonary disease is asthma.
20. A method of treating a non-pulmonary disease in which leukotrienes are a factor in a subject in need thereof comprising administrating to such subject an effective amount of a compound of claim 1 either alone or in combination with a pharmaceutically acceptable excipient.